AI Product

LabGenius — Biotechnology

EVA discovery platform integrating machine learning, robotic automation, and synthetic biology to design and optimize multispecific therapeutic antibodies; internal pipeline…

Intelligence Summary

Product
  • Active
  • Verified public sources
  • Developer LabGenius
  • Category Biotechnology
  • Status Active
  • Latest update 2012: LabGenius founded in London by James Field during PhD studies at Imperial College London.
  • Documentation Official page
  • Last reviewed Jul 2026
4 Technologies

Official product page

Target customer

Pharmaceutical and biotech partners seeking AI-designed multispecific antibodies, and investors evaluating ML-driven drug discovery with internal clinical-stage assets.

Features & capabilities

Industries: AI in Healthcare; Biotechnology

Related reports

Related insights

Overview

EVA discovery platform integrating machine learning, robotic automation, and synthetic biology to design and optimize multispecific therapeutic antibodies; internal pipeline including LGTX-101 and pharma partnership programs.

Product and company

LabGenius — Biotechnology is a verified product offering linked to the Brel Digital company profile for LabGenius.

Use cases

EVA discovery platform integrating machine learning, robotic automation, and synthetic biology to design and optimize multispecific therapeutic antibodies; internal pipeline including LGTX-101 and pharma partnership programs.

Target customer

Pharmaceutical and biotech partners seeking AI-designed multispecific antibodies, and investors evaluating ML-driven drug discovery with internal clinical-stage assets.

Technologies

Primary technologies assigned from the linked company profile: Deep Learning, Healthcare Analytics, Machine Learning, Predictive Analytics.

Sources and references

  • Official product / company source: https://labgeniustx.com/press-release-lgchem/
  • Supporting source: https://labgeniustx.com/team/

Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.

Last reviewed

This product profile was last reviewed on 2026-07-14.

Correction request

If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.

Features and capabilities

  • EVA discovery platform integrating machine learning, robotic automation, and synthetic biology to design and optimize mul
  • LGTX-101
  • pharma partnership programs

Extracted from the linked company product description already verified on Brel. No capabilities were invented.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Enquire about this product profile

Messages are delivered to contact@breldigital.com.